查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球戊型肝炎診斷測試市場 - 2022-2029
市場調查報告書
商品編碼
1129237

全球戊型肝炎診斷測試市場 - 2022-2029

Global Hepatitis E Diagnostic Tests Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

新型基於重組蛋白的戊型肝炎診斷試劑盒的開發有望推動市場增長。

Biotech Consortium India Limited 開發了一種高度敏感的檢測技術，用於檢測 HEV 感染，與其他市售檢測試劑盒相比。該技術基於豬 HEV 的開放閱讀框 2 開發戊型肝炎檢測試劑盒。目前的技術已將基因序列改變了 2%，增加了 HEV 蛋白的產生，促進了患者血清樣本中蛋白質的鑑定，並提高了診斷試劑盒的功效。這是一個可用於疫苗生產的技術平台。此外，該技術還具有檢測基因型 1 和 4 的優勢，靈敏度更高。因此，從上述陳述來看，預計將在預測期內推動市場。

約束

缺乏公眾意識、診斷方法的高成本和不充分的報銷規定是在預測期內阻礙市場發展的因素。

全球戊型肝炎診斷測試市場 - 行業分析

戊型肝炎診斷測試市場根據波特五力、報銷方案、定價分析和供應鍊等各種行業因素對市場進行了深入分析。

COVID-19 影響分析

COVID-19 大流行對醫療保健系統和市場產生了適度影響。 COVID-19 疫情擾亂了醫療保健系統，使提供基本臨床護理、戊型肝炎病毒抗體檢測和治療變得更加困難。結果，在大流行時未被診斷出患有戊型肝炎病毒的人隨後被發現患有更晚期的疾病，可能導致發病率和死亡率增加。此外，作為 COVID-19 大流行緩解措施的一部分，CDC 發布了關於推遲常規護理和推遲非必要任務的指南。有了這個建議，患者應避免不必要的面對面諮詢，並通過遠程醫療、患者門戶、電話和電子郵件與他們的醫療保健提供者溝通。

此外，大流行還將擾亂供應鍊和流程。許多公司將轉移到其他地區以確保產品可用性並保護其供應鏈。因此，從上面這句話來看，市場受到了影響，預計隨著經濟活動的恢復，市場將迅速獲得牽引力。

全球戊型肝炎診斷測試市場報告提供了大約 45 多個市場數據表、40 多個數字和 180 頁。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因子
    • 驅動程序
      • 新型基於重組蛋白的戊型肝炎診斷試劑盒的開發有望推動市場增長。
    • 限制因素
      • 預計診斷方法的高成本和不完善的報銷規定將阻礙市場增長。
    • 市場進入機會
    • 影響分析

第五章行業分析

  • 供應鏈分析
  • 定價分析
  • 未滿足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按產品類型

  • ELISA HEV IgM 檢測試劑盒
  • ELISA HEV IgG 檢測試劑盒
  • RT-PCR檢測試劑盒
  • 其他

第 8 章按測試類型

  • 血
  • 航班
  • 其他

第 9 章，最終用戶

  • 醫院
  • 診斷實驗室
  • 護理點
  • 其他

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準
  • 值得關注的重點公司列表

第 12 章公司簡介

  • 診斷自動化/Cortez Diagnostics, Inc.
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • EUROIMMUN Medizinische Labordiagnostika AG
  • Dia.Pro-Diagnostic Bioprobes s.r.l
  • Biokit S.A.
  • altona Diagnostics GmbH
  • ORGENTEC Diagnostika
  • Fortress Diagnostics
  • Mikrogen GmBH
  • Primerdesign Ltd
  • F. Hoffmann-La Roche Ltd.

第 13 章全球戊型肝炎診斷測試市場-DataM

簡介目錄
Product Code: DM5780

Market Overview

Hepatitis E Diagnostic Tests Market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 4.5 % during the forecast period (2022-2029).

The hepatitis E virus causes the enteric liver disease known as hepatitis E. (HEV). It belongs to the group of five known human hepatitis viruses (A, B, C, D, and E). Due to the feces in the water being a source of contamination, it is spread by fecal-oral contact. Hepatitis E cannot currently be diagnosed using an officially recognized test. Doctors rely on testing to identify the antibodies that fight the virus to diagnose hepatitis E correctly. It often relies on finding specific anti-HEV immunoglobulin M (IgM) antibodies to the virus in a person's blood; this is usually sufficient in regions where the disease is prevalent. For field use, rapid testing is available.

Market Dynamics

The development of a Novel Recombinant Protein-based Diagnostic Kit for Hepatitis E is expected to drive market growth.

Biotech Consortium India Limited has developed a technology that is a sensitive test for detecting HEV infection compared to other commercial assay kits. The technology is based on using Swine HEV's Open Reading Frame-2 for the development of Hepatitis E testing kits. The gene sequence underwent a 2-percent alteration in the current technology, leading to increased HEV protein production for better protein identification in the patient's sera sample and increased diagnostic kit effectiveness. This is a technology platform that can be used to create vaccines. Moreover, the technology benefits by detecting genotypes 1& 4 and has higher sensitivity. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

Lack of awareness among the population, high cost of diagnostic procedures and inadequate reimbursement regulations are some factors the market is expected to hamper in the forecast period.

Global Hepatitis E Diagnostic Tests Market - Industry Analysis

The hepatitis E diagnostic tests market provides in-depth analysis of the market based on various industry factors such as porter's five forces, reimbursement scenario, pricing analysis, supply chain etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. The COVID-19 pandemic has disrupted healthcare systems, making it more difficult to provide basic clinical care, hepatitis E virus antibody testing, and treatment. As a result, increased morbidity and mortality rates may result from those who had undiagnosed hepatitis E virus during the pandemic subsequently being found to have the disease in more advanced stages. Moreover, as part of the original COVID-19 pandemic mitigation initiatives, the CDC published guidelines on deferring routine clinical visits and delaying non-essential operations. By this advice, patients should avoid making unnecessary in-person visits and communicate with their healthcare practitioner via telemedicine, patient portals, phone, and email.

Additionally, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Segment Analysis

ELISA HEV IgM Test kits segment is expected to hold the largest market share in hepatitis E diagnostic tests market

The ELISA HEV IgM test kits segment is expected to dominate in 2021. HEV infection typically takes 2 to 6 weeks to develop. HEV RNA and anti-HEV IgM antibodies can be found at the time of diagnosis, followed by anti-HEV IgG antibodies. Positive anti-HEV IgM antibody results in serum can significantly indicate acute HEV infection. Anti-HEV IgM antibodies typically only remain positive for a few months (about 3-4 mo), although occasionally they do. The precise length of this response is still unknown. However, the anti-HEV IgG antibody is comparatively long-lasting.

Additionally, the avidity of the anti-HEV IgG antibody increases over time. Therefore, the demand for the ELISA HEV IgM Test kits increases. It is because it is a third-generation Enzyme ImmunoAssay (ELISA) for qualitatively determining IgG antibodies to Hepatitis E Virus in human plasma and sera. The kit is intended for the follow-up of HEV-infected patients. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

Asia Pacific region holds the largest market share in the global hepatitis E diagnostic tests market

In 2021, Asia Pacific accounted for the highest revenue share. The increasing prevalence of Hepatitis E cases, rising geriatric population, increasing consumption of pork, rise in adoption of Hepatitis E tests and product launches by the market players in the region are some factors the market is expected to boost in the forecast period. For instance, according to the National Center for Biotechnology Information, nearly 60% of blood donors in India have circulating anti-HEV IgG antibodies, indicating prior exposure to the virus, indicating that HEV infection and illness are extremely endemic country. The seroprevalence rates differ by age, with older people having greater rates. 5 Hepatitis E causes almost half of all instances of acute hepatitis and a comparable percentage of cases of acute liver failure (ALF).

Moreover, the middle and northern regions of India are where most of the country's pigs are found. Assam had more than two million people in 2019. Since swine is thought to be the main carrier of HEV, the largest pork intake suggests that the disease is spread through zoonotic agents. Thus, it has increased the demand for hepatitis E diagnostic tests, due to which the Asia Pacific is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the hepatitis E diagnostic tests market are Diagnostic Automation / Cortez Diagnostics, Inc., EUROIMMUN Medizinische Labordiagnostika AG, Dia.Pro - Diagnostic Bioprobes s.r.l , Biokit S.A., altona Diagnostics GmbH, ORGENTEC Diagnostika, Fortress Diagnostics, Mikrogen GmBH, Primerdesign Ltd, F. Hoffmann-La Roche Ltd.

altona Diagnostics GmbH:

Overview:

altona Diagnostics is a privately held medical diagnostic company headquartered in Hamburg-Altona, Germany. The business creates and produces in-vitro diagnostic tests for the DNA-based identification of pathogens like viruses, bacteria, and parasites. The company has over 20 years of experience in the molecular diagnostics industry and has received the ISO 13485 certification. Through subsidiaries and more than 40 distribution partners, altona Diagnostics provides its certified products to private and clinical laboratories worldwide. Additionally, altona Diagnostics' diagnostic tests are offered as ready-to-use kits based on real-time PCR technology. Over 50 CE-marked kits compatible with open real-time PCR platforms are available in the company's product line. Further, altona Diagnostics provides an automated workflow system that includes apparatus, specialized software, and chemistry for nucleic acid extraction.

Product Portfolio:

RealStar HEV RT-PCR Kit 2.0: The RealStar HEV RT-PCR Kit 2.0 is an in vitro diagnostic test, based on real-time PCR technology, for detecting and quantifying hepatitis E virus (HEV) specific RNA.

The global hepatitis E diagnostic tests market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The development of a Novel Recombinant Protein-based Diagnostic Kit for Hepatitis E is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of diagnostic procedures and inadequate reimbursement regulations are expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type Segment
  • 7.2. ELISA HEV IgM Test kits*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. ELISA HEV IgG Test Kits
  • 7.4. RT-PCR Test Kits
  • 7.5. Others

8. By Test Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 8.1.2. Market Attractiveness Index, By Test Type Segment
  • 8.2. Blood*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Stool
  • 8.4. Others

9. By End user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.1.2. Market Attractiveness Index, By End user Segment
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Diagnostic Laboratories
  • 9.4. Point of Care
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Diagnostic Automation / Cortez Diagnostics, Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. EUROIMMUN Medizinische Labordiagnostika AG
  • 12.3. Dia.Pro - Diagnostic Bioprobes s.r.l
  • 12.4. Biokit S.A.
  • 12.5. altona Diagnostics GmbH
  • 12.6. ORGENTEC Diagnostika
  • 12.7. Fortress Diagnostics
  • 12.8. Mikrogen GmBH
  • 12.9. Primerdesign Ltd
  • 12.10. F. Hoffmann-La Roche Ltd.

LIST NOT EXHAUSTIVE

13. Global Hepatitis E Diagnostic Tests Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Applications
  • 13.3. Contact Us